Cell Therapeutics adds three members to advisory board
This article was originally published in Scrip
Biopharmaceutical company Cell Therapeutics has appointed Alan List, Ross Levine and Brian Druker to its recently formed scientific advisory board. All three newly named members have expertise in blood cancer research and development. Dr List is president and CEO of Moffitt Cancer Center and a professor of internal medicine and oncology at the University of South Florida College of Medicine; Dr Levine is associate attending physician at Memorial Sloan-Kettering Cancer Center; and Dr Druker is director of the Knight Cancer Institute at Oregon Health and Science University (OHSU), chair of Leukemia Research at OHSU, and an Investigator of the Howard Hughes Medical Institute. The advisory board will advise on the development of Cell's oncology programs and evaluate new opportunities in the treatment of blood-related cancers.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.